Details for New Drug Application (NDA): 212579

NDA 212579 describes ATAZANAVIR SULFATE, which is a drug marketed by Amneal, Aurobindo Pharma, Cipla, Hetero Labs Ltd Iii, Laurus, Mylan, Teva Pharms Usa, and Zydus Pharms, and is included in eight NDAs. It is available from four suppliers. Additional details are available on the ATAZANAVIR SULFATE profile page.

The generic ingredient in ATAZANAVIR SULFATE is atazanavir sulfate. There is one drug master file entry for this compound. Five suppliers are listed for this compound. Additional details are available on the atazanavir sulfate profile page.

Mechanism of Action	Cytochrome P450 2C8 Inhibitors Cytochrome P450 3A Inhibitors Cytochrome P450 3A4 Inhibitors HIV Protease Inhibitors UDP Glucuronosyltransferases Inhibitors UGT1A1 Inhibitors

HIV Protease Inhibitors

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
ATAZANAVIR SULFATE	atazanavir sulfate	CAPSULE;ORAL	212579	ANDA	Laurus Labs Limited	42385-920	42385-920-48	10 BLISTER PACK in 1 CARTON (42385-920-48) / 6 CAPSULE in 1 BLISTER PACK (42385-920-06)
ATAZANAVIR SULFATE	atazanavir sulfate	CAPSULE;ORAL	212579	ANDA	Laurus Labs Limited	42385-920	42385-920-60	60 CAPSULE in 1 BOTTLE (42385-920-60)

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	EQ 150MG BASE
Approval Date:	Apr 30, 2021	TE:	AB	RLD:	No

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	EQ 200MG BASE
Approval Date:	Apr 30, 2021	TE:	AB	RLD:	No

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	EQ 300MG BASE
Approval Date:	Apr 30, 2021	TE:	AB	RLD:	No

Complete Access Available with Subscription